This launch of Epinephrine Injection multiple-dose Vial is eligible for 180 days of CGT exclusivity under section 505(j)(5)(B)(v) of the FD&C Act.
Glenmark’s consolidated revenue was at Rs. 3,387.6 crore as against Rs. 2,506.7 crore recording an increase of 35.1% YoY
Glenmark’s Clindamycin Phosphate Foam, 1% is bioequivalent and therapeutically equivalent to Evoclin Foam, 1%, of Mylan Pharmaceuticals.
According to IQVIATM sales data for the 12-month period ending November 2024, the Vitamin K1 Injectable Emulsion USP, 10 mg/mL market achieved annual sales of approximately $19.7 million
Glenmark's Travoprost Ophthalmic Solution USP, 0.004% is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z Ophthalmic Solution USP, 0.004% of Sandoz
Glenmark Pharmaceuticals Limited has informed that the USFDA has issued Form 483 with zero observations
India Business grew by 11.9% YoY to Rs. 1196.2 crore
he lower sales in the current quarter are mainly on account of a one?time impact on the company’s India business
European operations' revenue grew 58.4% to Rs 599.7 crore
Will continue to own a 7.84 per cent stake in Glenmark Life Sciences with the stake reduction
Subscribe To Our Newsletter & Stay Updated
